前列腺癌极限大分割放疗中同步整合加量至优势前列腺内病灶:直肠间隔物插入的影响
研究纳入12例不良中危或高危前列腺癌患者,比较直肠间隔物插入前后5次立体定向消融放疗容积调强弧形治疗计划,前列腺临床靶区处方40 Gy并同步整合加量至优势前列腺内病灶。间隔物插入后靶区覆盖更优且所有患者直肠剂量显著降低,25%患者可达到更高的病灶加量剂量,加量剂量取决于病灶位置及与尿道的邻近程度。
要点
- 间隔物插入后临床靶区V40Gy为98.4% vs 97.0%(p=0.012),靶区覆盖更优。
- 间隔物插入后12例患者直肠剂量均显著降低。
- 间隔物插入后6/12例可加量至50 Gy、3例至47.5 Gy,3例(25%)无法超过45 Gy。
核心结论
- 5次立体定向消融放疗前列腺临床靶区40 Gy联合同步整合加量至优势前列腺内病灶45–50 Gy可获得临床可接受的治疗计划。
- 达到的加量剂量取决于优势前列腺内病灶位置,主要受病灶与尿道邻近程度影响。
- 与间隔物插入前计划相比,25%的患者在间隔物在位时达到更高的优势前列腺内病灶剂量。
- 所有患者间隔物在位时直肠剂量显著降低且靶区覆盖更优。
研究设计与样本
- 研究采用12例不良中危或高危前列腺癌患者的24份计算机断层扫描图像。
- 每例患者至少生成两个治疗计划以比较间隔物插入前后的计划。
- 计划评估靶区覆盖、危及器官剂量及可达到的加量剂量水平。
主要发现
- 间隔物计划临床靶区V40Gy为98.4% vs 无间隔物计划97.0%(p=0.012),间隔物计划覆盖显著更优。
- 使用间隔物使本研究全部12例患者直肠剂量显著降低。
- 间隔物插入后6/12例患者可将优势前列腺内病灶加量至50 Gy而不违反剂量约束,3例患者可加量至47.5 Gy。
- 间隔物插入后3例患者(25%)即使间隔物在位也无法将优势前列腺内病灶加量至45 Gy以上。
- 无间隔物时6例患者(50%)仅在优势前列腺内病灶剂量降至45 Gy时才获得临床可接受计划,其中5例剂量限制结构为尿道(尿道计划风险体积V45Gy[cc]≤0.1 cc约束)。
关键数值与推荐
- 5次立体定向消融放疗容积调强弧形治疗前列腺临床靶区处方40 Gy,同步整合加量至优势前列腺内病灶最高50 Gy。
- 尿道计划风险体积V45Gy[cc]≤0.1 cc为剂量约束。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Boosting dominant intra-prostatic lesions (DILs) has the potential to increase the therapeutic ratio in prostate cancer radiotherapy. In this study, employing 5-fraction stereotactic ablative radiotherapy (SABR) volumetric modulated arc therapy (VMAT) to deliver 40 Gy to the prostate clinical target volume (CTV) while boosting the DIL up to 50 Gy was evaluated for patients before and after rectal spacer insertion. MATERIALS AND METHODS: 24 Computed Tomography (CT) scans of 12 prostate cancer patients with unfavourable intermediate or high risk prostate cancer were employed in this study. At least two treatment plans were generated for each patient to compare pre- and post-spacer insertion plans. Plans were evaluated for target coverage, organs-at-risk doses, and the achievable boost dose level. RESULTS: The CTV coverage was significantly better in plans with a spacer, V40Gy 98.4% versus 97.0% (p = 0.012). Using spacers significantly reduced rectal dose in all 12 patients in this study. It was possible to boost DIL to 50 Gy to without violating dose constraints in 6 of 12 patients and to 47.5 Gy in 3 patients post-spacer insertion. For 3 patients (25%) it was not possible to boost DIL above 45 Gy even with a spacer in situ. Without a spacer, for 6 patient (50%) clinically acceptable plan were only achieved when the DIL dose was lowered to 45 Gy. In five of these 6 patients the dose limiting structure was the urethra (urethra planning risk volume V45Gy [cc] ≤ 0.1 cc constraint). CONCLUSIONS: Clinically acceptable plans for 5 fraction SABR, 40 Gy to the prostate CTV, with a SIB to DIL (45-50 Gy) were achieved. The boost dose achieved was DIL location dependent and primarily affected by DIL's proximity to the urethra. Compared to plans before spacer insertion, higher DIL dose were achieved with spacer in situ for 25% of the patients. Moreover, significant reduction in rectal dose and better target coverage were also achieved for all patients with spacers in situ.
引用
- Osman SOS, Fairmichael C, Whitten G, et al. Simultaneous integrated boost (SIB) to dominant intra-prostatic lesions during extreme hypofractionation for prostate cancer: the impact of rectal spacers. Radiat Oncol. 2022. PMID: 35193630. doi:10.1186/s13014-022-02003-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。